Compare Mesoblast Limited (MESO) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Mesoblast Limited trades at $16.16 (market cap $2.17B), while iShares Broad USD Investment Grade Corporate Bond trades at $50.52. The key difference: Mesoblast Limited is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| MESO | USIG | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Fixed Income |
52-Week High | $20.96 | $52.69 |
52-Week Low | $12.88 | $50.50 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
USIG (iShares Broad USD Investment Grade Corporate Bond ETF) trades at $50.605, down 0.27% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings with RSI at 51.10. Recent corporate actions include dividend payments of $0.20-$0.21 per share. Short interest surged 63.4% in April 2026, indicating growing bearish sentiment among traders.
The ETF faces headwinds from rising short interest and bearish technical positioning. Investment grade corporate bond exposure provides stability but current market sentiment suggests caution. The dividend yield remains modest while technical indicators point to potential near-term pressure on the share price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
